Search research articles
Contact Us
Filters
Showing results (1101-1110 of 1,120) with videos related to
Page
of 112
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer
Ju-Won Roh, Jie Huang, Wei Hu, et al.
Lancet (London, England)
|
March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Proceedings : a Conference of the American Medical Informatics Association. AMIA Fall Symposium
|
January 1, 1996
Toward reusable software components at the point of care
M S Tuttle, D D Sherertz, N E Olson, et al.
Cancer Cell
|
October 6, 2009
Proteomic and genetic approaches identify Syk as an AML target
Cynthia K Hahn, Jacob E Berchuck, Kenneth N Ross, et al.
The Journal of Cell Biology
|
August 8, 2001
A protein interaction map for cell polarity development
B L Drees, B Sundin, E Brazeau, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Michael P Manns, Jonathan McCone, Mitchell N Davis, et al.
The New England Journal of Medicine
|
July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
John G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine
|
April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz, Alessandra Mangia, David Wyles, et al.
Antiviral Therapy
|
February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial
Robert A Ogert, John A Howe, John M Vierling, et al.
Veterinary Immunology and Immunopathology
|
March 18, 2006
Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004
J D Slater, D P Lunn, D W Horohov, et al.
Page
of 112
Search research articles
Search
Showing results (1101-1110 of 1,120) with videos related to
Sort By:
Page
of 112
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 18, 2014
Biologic effects of platelet-derived growth factor receptor α blockade in uterine cancer
Ju-Won Roh, Jie Huang, Wei Hu, et al.
Lancet (London, England)
|
March 19, 2013
Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Kris V Kowdley, Eric Lawitz, Israel Crespo, et al.
Proceedings : a Conference of the American Medical Informatics Association. AMIA Fall Symposium
|
January 1, 1996
Toward reusable software components at the point of care
M S Tuttle, D D Sherertz, N E Olson, et al.
Cancer Cell
|
October 6, 2009
Proteomic and genetic approaches identify Syk as an AML target
Cynthia K Hahn, Jacob E Berchuck, Kenneth N Ross, et al.
The Journal of Cell Biology
|
August 8, 2001
A protein interaction map for cell polarity development
B L Drees, B Sundin, E Brazeau, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
October 15, 2013
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials
Michael P Manns, Jonathan McCone, Mitchell N Davis, et al.
The New England Journal of Medicine
|
July 24, 2009
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection
John G McHutchison, Eric J Lawitz, Mitchell L Shiffman, et al.
The New England Journal of Medicine
|
April 24, 2013
Sofosbuvir for previously untreated chronic hepatitis C infection
Eric Lawitz, Alessandra Mangia, David Wyles, et al.
Antiviral Therapy
|
February 15, 2013
Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial
Robert A Ogert, John A Howe, John M Vierling, et al.
Veterinary Immunology and Immunopathology
|
March 18, 2006
Report of the equine herpesvirus-1 Havermeyer Workshop, San Gimignano, Tuscany, June 2004
J D Slater, D P Lunn, D W Horohov, et al.
Page
of 112